Citations

Clear

5 citation(s) found for "Stephens, Haily".

Early Treatment Failure in Patients Receiving Ciltacabtagene‐Autoleucel for Relapsed/Refractory Multiple Myeloma
Lim, Kenneth J C , Kumar, Shaji, Chhabra, Saurabh , Tan, Melinda Si Yun , Dooley, Katharine, Corraes, Andre De Menezes Silva , Gertz, Morie A. , Hwa, Yi L. , Stephens, Haily, Kapoor, Prashant , Kourelis, Taxiarchis, Warsame, Rahma, Abdallah, Nadine , Bergsagel, P. Leif, Yadav, Udit, Geyer, Susan M. , Ailawadhi, Sikander, Lin, Yi, Zanwar, Saurabh , Chhabra, Saurabh , Tan, Melinda , Gertz, Morie A , Hwa, Lisa, Cook, Joselle M , Binder, Moritz , Abdallah, Nadine H , Wiedmeier-Nutor, Julia E , Geyer, Susan , Rajkumar, S Vincent , Fonseca, Rafael , Zanwar, Saurabh S , Lim, Kenneth J C , Kumar, Shaji , Parrondo, Ricardo D , Dooley, Katharine , Stephens, H. J. B., Kourelis, Taxiarchis , Warsame, Rahma , Cook, Joselle , Binder, Moritz , Bergsagel, P. Leif , Yadav, Udit , Wiedmeier, Julia E. , Rajkumar, S. Vincent , Ailawadhi, Sikander , Fonseca, Rafaël

Mayo Clinic

American Journal of Hematology | June 26, 2026 | Volume: 101 | Issue: 9 | Pages: 2269-2279

10.1002/ajh.70425 | PMID 42351384 Get It

ABSTRACT Ciltacabtagene autoleucel (cilta‐cel) has demonstrated excellent efficacy and long‐term disease control in patients with relapsed/refractory multiple myeloma (RRMM). However, a proportion of patients experience early treatment failures. We investigated clinical factors associated with early progression or death (within 12 months) in patients with RRMM receiving standard‐of‐care cilta‐cel across the three Mayo clinic centers. Patients with a follow‐up of at least 12 months or progression or death within 12 months from infusion were included. Of the patients with early treatment failure ( n = 52), 69% had progressive disease and 31% had a non‐relapse mortality (NRM) event. In patients without early treatment failure ( n = 164), 13% of events were NRM. Among pretreatment factors, prior BCMA‐directed therapy, presence of extramedullary disease and a CAR‐HEMATOTOX score of ≥ 2 were independent predictors of early progression or death. The utilization of cilta‐cel in earlier lines of treatment (1–3 vs. 4 or more) demonstrated comparable PFS (12‐month PFS 73% vs. 77%, p = 0.94). Measurable residual disease positivity in the bone marrow at 3 months (11/197 patients) identified a small but high‐risk group with an increased risk of early treatment failure (OR 5.68; p = 0.012). Patients with less than a complete response on a FDG PET/CT at 3 months also had an increased risk of early treatment failure (OR 11.8; p < 0.0001). Our findings may help identify patients at high‐risk for early adverse outcomes despite receiving highly effective therapy, and support consideration of novel therapeutic strategies within a clinical trial setting.
Diagnosis and management of immune effector cell–associated enterocolitis after ciltacabtagene autoleucel
Lim, Kenneth J C , Lee, Hee Eun , Chen, Zongming Eric, Bledsoe, Adam C. , Parrondo, Ricardo , Chhabra, Saurabh , Dooley, Katharine , Corraes, Andre De Menezes Silva , Gertz, Morie A. , Hwa, Y., Stephens, Haily, Kapoor, Prashant , Tan, Melinda S.Y., Kourelis, Taxiarchis , Warsame, Rahma , Yadav, Udit , Wiedmeier-Nutor, Julia Erin, Geyer, Susan, Kumar, Shaji , Chowla, Navreet , Lin, Y., Bledsoe, Adam C , De Menezes Silva Corraes, Andre , Gertz, Morie A , Hwa, Lisa, Cook, Joselle M , Binder, Moritz , Bergsagel, P. Leif , Yadav, Udit , Wiedmeier-Nutor, Erin, Fonseca, Rafael , Kumar, Shaji K , Chowla, Navreet , Parrondo, Ricardo D , Chhabra, Saurabh , Lim, Kenneth J C , Stephens, H. J. B., Cook, Joselle , Binder, Moritz , Bergsagel, P. Leif , Geyer, Susan M. , Ailawadhi, Sikander , Fonseca, Rafaël

Mayo Clinic

Blood Advances | April 10, 2026 | Volume: 10 | Issue: 13 | Pages: 4495-4507

10.1182/bloodadvances.2025018853 | PMID 41961998 Get It

Abstract Immune effector cell–associated enterocolitis (IEC-EC) has been observed after ciltacabtagene autoleucel (cilta-cel [Carvykti]) chimeric antigen receptor T-cell (CAR-T) therapy. It is associated with dismal outcomes and is poorly characterized. Here, we examined its clinical features, risk factors, and proposed management strategies. Among the 229 consecutive patients who received cilta-cel at Mayo Clinic, 9 (3.9%) presented with a nonresolving, nonbloody, grade 3 diarrhea, often requiring prolonged total parenteral nutrition. Gastrointestinal coinfections were seen in most patients. Median time from CAR-T infusion to symptom onset was 85 days (range, 35-166), and there appeared to be a latency from symptom onset to endoscopic evaluation. Histopathology findings resembling a graft-versus-host disease pattern of mucosal injury were most seen on duodenal biopsies, whereas 2 cases had patterns akin to a T-cell lymphoproliferative disorder (1 CD4+ and 1 CD8+). Independent associated factors for IEC-EC included high-risk disease as defined by the International Myeloma Society and International Myeloma Working Group, prolonged cytokine release syndrome, and antecedent delayed neurotoxicity. Response to first-line therapy comprising IV or oral corticosteroids, bile acid sequestrants, IV immunoglobulin, and antimicrobial-directed therapy was poor, with no durable responses. Biologic therapy appeared to induce durable responses in 3 of the 5 patients (2/2 vedolizumab; 1/3 infliximab); none of the responders had gastrointestinal coinfection. Early gastroenterology input for endoscopic evaluation with the inclusion of duodenal biopsy is a key component for diagnosis. Early institution of biologic therapy after failure of a short course of corticosteroids should be considered.
Prophylactic dexamethasone to reduce risk of cilta-cel associated immune effector cell delayed neurotoxicity
Dooley, Katharine , Corraes, Andre De Menezes Silva , Carabenciov, Darin D., Hwa, Yi L. , Stephens, Haily, Kapoor, Prashant , Tan, Melinda Si Yun , Kourelis, Taxiarchis , Warsame, Rahma , Bergsagel, P. Leif , Yadav, Udit , Wiedmeier, Julia E. , Geyer, Susan M. , Zanwar, Saurabh , Abdallah, Nadine , Kumar, Shaji, Ζεκερίδου, Αναστασία , Wiedmeier-Nutor, Julia E , Lim, Kenneth J C , Parrondo, Ricardo D , Chhabra, Saurabh , Gertz, Morie A. , Stephens, Haily, Cook, Joselle , Binder, Moritz , Bergsagel, P. Leif , Ailawadhi, Sikander , Fonseca, Rafaël , Kumar, Shaji , Lin, Yi

Mayo Clinic

Blood | December 4, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 5953-5953

10.1182/blood-2025-5953 Get It

Abstract Introduction Cila-cel is associated with a 10-15% risk of delayed neurotoxicity (DNT) with rates of cranial nerve palsies (IEC-NP) and parkinsonism (IEC-PKS) seen at a rate of 10% and 1-4% respectively and can occur as early as 3-4 weeks after infusion. We and others have shown that high post-infusion peak absolute lymphocyte count (ALCpeak) of &gt;3x10^9/L is associated with an increased risk of delayed neurotoxicity (Lim et al., ASCO 2025) whilst the risk was negligible (~1%) when ALCpeak fell below that threshold. Since December 2024, we implemented prophylactic administration of dexamethasone (PPX DEX) when ALC was &gt;3x10^9/L (defined as high ALCpeak). Outcome of these patients are described here. Methods Analysis of clinical outcome included 230 pts treated between Feb 2022 and Nov 2024 as a historical cohort and 102 patients treated between Dec 2024 and May 2025 after the introduction of dexamethasone prophylaxis using an oral dose of 10mg twice a day for at least three days in the high ALCpeak cohort. Results No significant differences were seen between the new and historical cohort in pre-lymphodepletion disease burden (bone marrow plasma cell %, involved light chain or M-spike level), and rates of all/high-grade CRS or ICANS, IEC-HS and rates of tocilizumub use. Median follow-up in the new cohort of 102 pts was 3.6 months (95% CI 3.3-4.2). Eleven (10.8%) developed DNT [3 (2.9%) with IEC-PKS, 8 (7.8%) with IEC-NP]. High ALCpeak of &gt;3x10^9/L was observed in 51 (50%) pts. Among pts with high ALCpeak, DNT was observed in 10 (20%) pts [3 (5.9%) with IEC-PKS, 7 (13.7%) with IEC-NP] whereas among 51 pts with ALCpeak &lt;3x10^9/L, DNT was observed in 1 (2%) pt [1 (2%) with IEC-NP]. In the high ALCpeak cohort, 38 (75%) received DEX [6 (12%) for toxicity management, 32 (63%) PPX DEX]. Of the 38 pts treated with DEX, DNT was observed in 6 (16%) pts (2 (5.3%) IEC-PKS, 4 (10.5%) IEC-CNP). We next compared DNT rates between this new cohort of high ALCpeak pts receiving DEX (n=38) against the historical cohort with high ALCpeak (n=98). Estimated 90-day DNT by Kaplan-Meier method was (19.2% vs 20.5%; p=0.53): IEC-PKS (5.8% vs 7.2%; p=0.60) and IEC-NP (11.7% vs 13.3%; p=0.58). In patients with high ALCpeak, the use of DEX did not appear to significantly reduce the risk of DNT compared to historical controls (HR 0.76, 0.33-1.78), IEC-PKS (HR 0.67, 0.14-3.10) or IEC-NP (0.73, 0.24-2.23). We next compared ALC expansion over the first month post CAR-T infusion (area under the curve, AUC). Among the new cohort of 102 patients, no difference was seen in the AUC of pts who received DEX but did not develop DNT vs those who developed DNT (31.0 vs 57.9, p=0.28); No difference in AUC was seen in the new high ALCpeak cohort receiving DEX vs the historical cohort with high ALCpeak (36.0 vs 43.8, p=0.15) Of the eight cases of IEC-NP, 4 received PPX DEX. No noticeable differences were observed in the severity of presentation, laterality of cranial nerve involvement and rates of multiple cranial nerve involvement between these 4 cases who received PPX DEX and the 16 cases from the historical cohort. At the time of database freeze, 3 of the 4 cases had resolved and 1 was improving. Median time to complete symptom resolution was 38 days vs 69 days in the historical cohort. Of the three cases of IEC-PKS, 2 received PPX DEX. Median time to symptom onset for IEC-PKS was 46 days (vs. 24 days in historical cohort). Both cases had severe symptoms non-responsive to first line high-dose methylprednisolone, second line intrathecal chemotherapy and third line high-dose cyclophosphamide. Both pts subsequently died from sepsis 28 and 67 days post-cyclophosphamide. Conclusion While ALCpeak &gt;3x10^9/L predicts risk of DNT in pts treated with cilta-cel, the use of PPX DEX does not appear to significantly reduce ALC expansion and does not appear to significantly reduce the risk of DNT, IEC-PKS or IEC-NP. Other strategies to reduce ALC or alter T cell functions may need to be considered.
Investigating the association between peak post-infusion absolute lymphocyte count (ALC) and delayed toxicity in myeloma (MM) patients (pts) receiving cilta-cel.
Dooley, Katharine , Corraes, Andre De Menezes Silva , Hwa, Yi L. , Stephens, Haily, Kapoor, Prashant , Tan, Melinda, Kourelis, Taxiarchis , Warsame, Rahma , Cook, Joselle , Geyer, Susan, Kumar, Shaji, Lim, Kenneth J C , Parrondo, Ricardo D , Chhabra, Saurabh , Gertz, Morie A. , Stephens, Haily, Cook, Joselle , Binder, Moritz , Bergsagel, P. Leif , Kumar, Shaji , Ailawadhi, Sikander , Fonseca, Rafaël , Lin, Yi

Mayo Clinic

Journal of Clinical Oncology | May 28, 2025 | Volume: 43 | Issue: 16_suppl | Pages: 7522-7522

10.1200/jco.2025.43.16_suppl.7522 Get It

7522 Background: Movement and neurocognitive treatment emergent adverse events (MNTs), cranial nerve palsies (CNPs) and immune-effector cell enterocolitis (IEC-EC) are late onset toxicities associated with cilta-cel and are associated with significant morbidity and mortality. We aimed to identify predisposing risk factors to allow for formulating risk-reduction strategies. Methods: Retrospective study of MM pts who received FDA approved cilta-cel at Mayo Clinic between Feb 2022-Dec 2024. Interrogated factors included demographics, disease and treatment characteristics, and selected lab values at different time points. In odds ratio (OR) analyses, pts were divided by toxicity type (1) No delayed toxicity (2) MNT (3) IEC-EC without MNT (4) isolated CNP. Differences between pts in the MNT, IEC-EC and CNP groups were compared separately in a pairwise manner vs. those with no delayed toxicity. Results: Of 235 pts, 26 (11%) had delayed toxicity [MNT = 8 (3%), IEC-EC = 9 (4%), CNP = 14 (6%)]; 3 pts had both MNT/IEC-EC and 2 had both CNP/IEC-EC. Median onset from CAR-T infusion for MNT, IEC-EC and CNP was 19 (range 8-96), 106 (35-169) and 21 (7-43) days respectively. Of 164 evaluable pts, those who had ICANS had increased odds for any delayed toxicity (OR 4.7; 95% CI 1.6-13.8). Pts who had ICANS (OR 7.7; 1.6-36.9), HLH/MAS (OR 6.2; 1.1-6.7) and Ferritin >400mcg/L at time of lymphodepletion (OR 6.3; 1.5-32) had increased odds for MNTs. Pts who received alkylator-based bridging therapy had increased odds (OR 6.1; 1.1-35) for IEC-EC. Analysis of serial post-CAR infusion lab values showed that peak ALC was the most significant variable with differences between groups shown in table. Median time to peak ALC was 12 days (IQR 11-13). ROC analysis determined peak ALC >3 x 10 9 /L as a meaningful cut point. Pts with peak ALC >3.0 x 10 9 /L had increased odds of developing any delayed toxicity (OR 9.3; 3.5-29.3), MNT and CNP (table). Absolute risk of any delayed toxicity was 33% in pts with peak ALC >3 x 10 9 /L vs 5% without. At this threshold, number needed to treat was 3.6. Conclusions: Real-world data shows that cilta-cel associated delayed toxicity is seen in ~10% of patients, with specific toxicity rates between 4-8%. Factors associated with these toxicities predominantly occur in the post CAR-T infusion period. Given that ALC expansion in the first 2 weeks correlate with CAR-T expansion, peak ALC is potentially predictive of toxicity and 3 x 10 9 /L may be an interventional threshold for primary prophylaxis. Peak ALC by toxicity groups. No ToxN=138 MNTN=8 CNPN=12 IEC-ECN=6 p value Peak ALC (10 9 /L), median (IQR) 1.8 (1.0-4.1) 6.2 (4.8-14.4) 4.3 (3.2-6.7) 3.6 (1.9-5.2) <0.001 1 ALC >3 x 10 9 /L, n (%) 43 (31%) 7 (88%) 10 (83%) 4 (67%) <0.001 2 Odd Ratios vs no Tox 3 , 95% CI 15.5 (2.6-293.7) 11.0 (2.8-73.9) 4.4 (0.8-25.0) 1 Wilcoxon/Kruskal-Wallis Tests, 2 Chi square test, 3 Logistic regression analysis.
Pre-Apheresis Prediction of Toxicity and Response in Patients Receiving BCMA-Directed CAR-T for Relapsed/Refractory Multiple Myeloma
Santos, David M. Cordas dos , Corraes, Andre De Menezes Silva , Alsdorf, Winfried , Purcarea, Anna , Freeman, Ciara L. , Gaballa, Mahmoud , Gonzalez, Rebecca , Waqar, Syed Hamza Bin , Hwa, Yi L. , Shahbaz, Wajma, Spiess, Genevieve, Stephens, Haily, Hecker, Judith S. , Subklewe, Marion, Patel, Krina K. , Lin, Yi , Rejeski, Kai , Hansen, Doris K. , Puglianini, Omar Castañeda , Dillard, Christen , Frenking, Jan Hendrik , Chhabra, Saurabh , Friedrich, Mirco , Jain, Michael D. , Parrondo, Ricardo D , Pasvolsky, Oren , Shouval, Roni , Stephens, Haily, Theurich, Sebastian , Bassermann, Florian C. , Raab, Marc S. , Weisel, Katja C , Locke, Frederick L. , Subklewe, Marion

Mayo Clinic

Blood | December 5, 2024 | Volume: 144 | Issue: Supplement 1 | Pages: 895-895

10.1182/blood-2024-208376 Get It

Introduction: Recent efforts have shed light on the clinical and laboratory factors associated with toxicity and response to BCMA-directed CAR-T therapy in patients with relapsed/refractory multiple myeloma (RRMM). However, a major limitation of current scoring systems lies in their assessment at time of lymphodepletion. Because they are not determined before apheresis, they are ill-equipped to guide patient selection, anticipate level-of-care, or plan pre-emptive toxicity management strategies. We therefore aimed to characterize early predictors of CAR-T toxicity and response. Study Design: In this multicenter observational study, we examined demographic, clinical, and laboratory data across three distinct timepoints: indication (e.g., treatment decision), apheresis, and pre-lymphodepletion (LD). CRS and ICANS were graded according to ASTCT criteria. Hematotoxicity (ICAHT) was graded using EHA/EBMT criteria. Early infections (day 0-100) were defined based on microbiologic data or as a clinical infection syndrome, and graded per Hill et al, Blood 2018. Kaplan-Meier estimates of progression-free (PFS) and overall survival (OS) were compared by log-rank test. Cox proportional hazard models were applied to explore associations between pre-apheresis risk factors and key toxicity and survival outcomes. The CAR-HEMATOTOX (HT) score - encompassing markers of inflammation (e.g., CRP, ferritin) and marrow reserve (e.g., hemoglobin, ANC, platelet count) - was determined at each timepoint (Rejeski et al, Blood 2021). Results: We included 530 RRMM patients treated with standard-of-care cilta-cel (n=184) or ide-cel (n=346) across nine centers. Median age was 65 (range 31-88), median ECOG was 1 (IQR 0-1), and patients received a median of 5 prior lines of therapy (IQR 4-7). The median time from indication to apheresis was 16 days (IQR 7-52), while the median time from apheresis to infusion was 56 days (IQR 46-69). The proportion of high-risk patients by HT score did not change between the pre-apheresis and LD timepoints (19% vs. 20%, p=0.82). Most patients stayed either low-risk (n=388, 73.2%) or high-risk (n=68, 12.8%). However, 35 patients (6.6%) shifted from high-to-low risk, while 39 patients (7.4%) progressed from low-to-high risk - reflecting their response to bridging therapies. We noted considerable differences in morbidity and mortality based on the pre-apheresis HT score. Compared to their low-risk counterparts (score 0-2, n=427), high-risk patients (score ≥3, n=103) were hospitalized longer (12 vs. 15 days, p=0.009) and required more frequent ICU admissions (6% vs. 12%, p=0.05). They exhibited more severe early cytopenias (G3+: 8% vs. 25%, p&lt;0.001) and late cytopenias (G3+: 7% vs. 21%, p&lt;0.001), resulting in increased use of TPO agonists and stem cell boosts. Grade 3 or higher ICANS was also more common in HThigh patients (3% vs. 11%, p=0.006), as were severe infections (14% vs. 27%, p=0.007). We found increased non-relapsed mortality in HThigh patients (1-yr NRM 4.6% vs. 16.1%, p&lt;0.001), but no significant difference in the occurrence of secondary malignancies (p&gt;0.9). With a median follow-up of 12.4 months, HThigh patients showed inferior PFS (1-yr PFS 29% vs. 63%, p&lt;0.0001) and OS (1-yr OS 49% vs. 83%, p&lt;0.0001). Transitioning from a low-to-high score was linked to poor survival (1-yr PFS 26%), while the shift from high-to-low risk was associated with favorable outcomes (1-yr PFS 51%). In a multivariable Cox regression model of pre-apheresis features, a high HT score (aHR 2.52, p&lt;0.0001), prior anti-BCMA therapy (aHR 1.55, p=0.04), history of extramedullary disease (aHR 1.42, p=0.02), and penta-refractoriness (aHR 1.45, p=0.02) were independently associated with PFS. Notably, the presence of more than 3 of these high-risk features defined an ultra-high-risk cohort of 28 patients (5.3%) with particularly dismal survival (1-year PFS 15%). Conclusions: Leveraging granular pre-apheresis data from a large international cohort, we identify early markers of toxicity and response in CAR-T-treated RRMM patients. The HT score - reflecting baseline inflammation and hematopoietic reserve - identified high-risk patients likely to benefit from pre-emptive toxicity mitigation strategies such as prophylactic stem cell collection. Most importantly, we characterize a small yet ultra-high-risk group of RRMM patients in need of more effective bridging and therapeutic options.